At a glance
ClinicalIndex Comparison RecordN/ACompleted· 571 enrolled
Drug / intervention
SARS-CoV-2 IgG Antibody Testing Kitother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers and Candidacy for Convalescent Plasma Therapy/Prophylaxis
In Brief
A clinical study evaluating SARS-CoV-2 IgG Antibody Testing Kit for SARS-CoV-2. Completed, enrolled 571 participants across 1 site.
Detailed Summary
The purpose of this study is to validate the use of a rapid, at home, point-of-care (POC) SARS-CoV-2 IgG antibody test in high risk healthcare workers. Additionally, we would like to evaluate the incidence of seroconversion in this high-risk population and to identify possible candidates for convalescent plasma donation for therapy/prophylaxis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSARS-CoV-2
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
Enrollment StartApr 2020
First PostedApr 2020
Primary CompletionNov 2020
Study CompletionJan 2021
TodayJul 2026
First PostedApr 6, 2020
Enrollment StartApr 1, 2020
Primary CompletionNov 1, 2020
Study CompletionJan 1, 2021
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 6.2 years ago
Interventions
SARS-CoV-2 IgG Antibody Testing Kitother
A, finger prick, at home test for SARS-CoV-2 IgG Antibodies.